Development programs are becoming more scientifically demanding, regulatory requirements are changing, and global supply chains remain under pressure. At the same time, R&D portfolios must be focused, and investments concentrated where scientific prospects, patient needs, and economic potential converge.
The pharmaceutical industry is under high innovation pressure and increasing international competition. New modalities expand therapeutic possibilities but also increase development risks and requirements for evidence, production, and market access. Simultaneously, regulatory frameworks and demands for resilient production and supply chains are changing. For companies, this increases the pressure to focus development programs early and concentrate capital, capacities, and management attention on the most promising assets.
New mechanisms of action and modalities expand the pipeline but also increase costs and complexity. At the same time, competition for scientific innovation is growing – especially from the USA and Asia.
Clinical development increasingly takes place under parallel requirements from regulatory authorities, HTA, and payers. Decisions on endpoints, study populations, or comparative therapies can thus have an impact far beyond the actual approval.
Supply bottlenecks, dependencies on active ingredients and intermediates, and increasing demands for supply security are changing investment decisions in production and the supply chain.
Portfolio decisions, cross-functional development plans, external partners, distributed data, and regulatory requirements intertwine over long development cycles. Five areas of tension particularly shape planning.
Drug development portfolios change with each decision point. Development risk, expected value, costs, and future resource requirements must be considered together. Stage gates, go/no-go decisions, and PTRS thus become not only governance elements but also parameters for risk-weighted portfolio, cost, and capacity scenarios.
Multi-year portfolio roadmaps meet detailed clinical, CMC, and regulatory plans with different responsibilities and planning depths. Integrated development planning connects master and detailed plans via common milestones, dependencies, and decision points, without replacing the specialized planning of the functions.
CROs, CDMOs, and scientific partners influence milestones, deliverables, costs, and risks along the critical path. Their relevant contributions must become part of the same control, even though operational planning and responsibility sometimes lie outside one's own organization.
Decision-relevant information originates in different specialized systems. At the same time, GLP, GCP, and GMP environments require traceable changes, approvals, and audit trails. A robust PPM layer connects the relevant data without unnecessarily duplicating CTMS, ERP, Finance, or document systems.
Portfolio reviews require more than a current status view. What-if scenarios must show how delays, additional studies, a changed scope, or the stopping of an asset impact milestones, costs, resources, and downstream decisions – before a decision is made.
We combine deep process understanding in the pharmaceutical industry with proven industry best practices and comprehensive technological expertise. This results in planning solutions that fit your control logic, organization, and system landscape.
As close to standard as possible. As individual as necessary.
For implementation, we rely on established PPM platforms – tailored to your individual challenge.
Director of Delivery
„The success of a development portfolio also depends on whether the right specialized resources are available at the right time. With our Enterprise PPM solutions, we ensure that portfolio decisions do not remain at the strategic level but are consistently reflected in resources and capacities.“
